Nathan L. Mata sold $156k of BLTE
Chief Scientific Officer at BELITE BIO, INC. 1,000 shares at an average of $155.82, traded Apr 29, 2026, filed Apr 30, 2026.
Score components
- +15RoleOfficer
- +11Trade size$156k at market
- +5Share of holdings soldSold 15% of holdings
- 0ClusterNo other insider selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -9.4%, 3m +0.5%, 6m -.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001193125-26-197320, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Apr 29, 2026 | SOpen-market sale American depositary share10b5-1 | -278 | $154.58 | $43k | 6,388 | Apr 30, 2026 |
| Apr 29, 2026 | SOpen-market sale American depositary share10b5-1 | -259 | $155.52 | $40k | 6,129 | Apr 30, 2026 |
| Apr 29, 2026 | SOpen-market sale American depositary share10b5-1 | -339 | $156.43 | $53k | 5,790 | Apr 30, 2026 |
| Apr 29, 2026 | SOpen-market sale American depositary share10b5-1 | -102 | $157.39 | $16k | 5,688 | Apr 30, 2026 |
| Apr 29, 2026 | SOpen-market sale American depositary share10b5-1 | -22 | $158.19 | $3,480 | 5,666 | Apr 30, 2026 |
Related signals
Other insiders at BELITE BIO, INC and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 4Weak | BELITE BIO, INC | Hendrik Peter Scholl Chief Medical Officer | $83k 500 shares | -3% | |
| 55Moderate | BELITE BIO, INC | Hao-Yuan Chuang Chief Financial Officer | $13M 67,395 shares | -72% | |
| 58Moderate | BELITE BIO, INC | Yu-Hsin Lin Chief Executive Officer | $19M 100,435 shares | -59% | |
| 21Weak | BELITE BIO, INC | Yu-Hsin Lin Chief Executive Officer | $66k 365 shares | -0% | |
| 18Weak | BELITE BIO, INC | Hao-Yuan Chuang Chief Financial Officer | $66k 367 shares | -0% | |
| 50Moderate | BLTEsell BELITE BIO, INC | Hendrik Peter Scholl Chief Medical Officer | $1.5M 10,000 shares | -40% | |
| 50Moderate | BLTEsell BELITE BIO, INC | Hendrik Peter Scholl Chief Medical Officer | $1.4M 10,000 shares | -29% | |
| 25Weak | BELITE BIO, INC | Nathan L. Mata Chief Scientific Officer | $102k 666 shares | -100% | |
| 26Weak | BELITE BIO, INC | Nathan L. Mata Chief Scientific Officer | $154k 1,000 shares | -60% | |
| 16Weak | BELITE BIO, INC | Nathan L. Mata Chief Scientific Officer | $156k 1,000 shares | -38% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.